ReviewOcular oncology and pathology2017
Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.
Review in Ocular oncology and pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 54 citations in OpenAlex.
- Clinical features and outcomes of melanoma involving eyelid and conjunctiva.Canadian journal of ophthalmology. Journal canadien d'ophtalmologie · 2026Article
- [New systemic treatment approaches for conjunctival melanoma].Die Ophthalmologie · 2025Review
- Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights.International journal of molecular sciences · 2025Review
- [Bilateral, central serous chorioretinopathy under BRAF(B-rapidly accelerated fibrosarcoma)-/MEK (mitogen-activated protein kinase kinase)-inhibitor therapy in metastatic cutaneous melanoma.]Die Ophthalmologie · 2025Article
- Conjunctival melanoma: comprehensive insights into clinical features, genetic alterations, and modern treatment approaches.Pathology oncology research : POR · 2025Review
- Development and validation of a nomogram to predict overall survival of conjunctival melanoma: a population-based study.Translational cancer research · 2024Article
- Review
- Molecular Genetics of Conjunctival Melanoma and Prognostic Value ofInternational journal of molecular sciences · 2021Article
- Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway.Cell death & disease · 2021Article
- Genetics of Ocular Melanoma: Insights into Genetics, Inheritance and Testing.International journal of molecular sciences · 2020Review
- PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome.International journal of molecular sciences · 2020Article
- Transcriptional characterization of conjunctival melanoma identifies the cellular tumor microenvironment and prognostic gene signatures.Scientific reports · 2020Article
- [Personalized medicine in the treatment of periocular tumors : Targeted treatment and use of immune checkpoint inhibitors].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020Review
- Dabrafenib and Trametinib for BRAF-Mutated Conjunctival Melanoma.Ocular oncology and pathology · 2020Article
- Management Issues in Conjunctival Tumours: Conjunctival Melanoma and Primary Acquired Melanosis.Ophthalmology and therapy · 2019Review
- Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma.International journal of molecular sciences · 2019Review
- Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy.Cancer biology & medicine · 2019Article
- Two Late Recurrences of Conjunctival Melanoma.Ocular oncology and pathology · 2019Article
- Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights.Clinical ophthalmology (Auckland, N.Z.) · 2019Review
- [Conjunctival melanoma : Standard operating procedures in diagnosis, treatment and follow-up care].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn this review, we outline similarities between conjunctival and skin melanoma as well as the effectiveness of combined BRAF/MEK inhibition in melanoma, and discuss the applicability of these agents in conjunctival melanoma.
methodsThe study provides a PubMed literature review.
resultsConjunctival melanoma and skin melanoma are genetically and phenotypically related. Both tumors typically harbor BRAF mutations in more than 50% of cases. New targeted therapies in metastatic skin melanoma include selective inhibition of BRAF and MEK. Combined BRAF/MEK inhibition has revolutionized the treatment of metastatic skin melanoma, significantly improving patients' prognoses. While these new substances have been investigated extensively in the treatment of skin melanoma, comparable studies in conjunctival melanoma do not exist owing to the rarity of the malignancy.
conclusionsThe application of combined BRAF/MEK inhibition in metastatic or unresectable conjunctival melanoma shows great potential for improving patients' prognoses. Future studies are needed to investigate the assumed benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.